Endoscopic papillectomy for the treatment of duodenal papillary adenoma: a promising treatment approach

Le résumé fourni par la source

This study evaluated the efficacy and safety of endoscopic papillectomy for duodenal papillary adenoma through a retrospective analysis of 18 patients (11 males, 7 females) treated at the Endoscopy Center of Jiangsu Provincial Hospital of Chinese Medicine between January 2022 and December 2024. All patients underwent complete lesion resection in a single session, with 11 cases managed by endoscopic mucosal resection (EMR) and 7 by endoscopic submucosal dissection (ESD), achieving an R0 resection rate of 94.44% (17/18). Postoperative stenting included pancreatic duct placement in 11 patients, biliary duct placement in 2 patients, and dual pancreaticobiliary stenting in 5 patients. Delayed bleeding occurred in 9 patients, all successfully managed by endoscopic hemostasis. These findings demonstrate that endoscopic papillectomy is a clinically effective and safe therapeutic option for duodenal papillary adenoma, particularly when combined with targeted stent placement and immediate hemostatic intervention.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.